Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
COMBINATION OF ETOPOSIDE, IDARUBICIN, CYCLOPHOSPHAMIDE, VINCRISTINE, PREDNISONE AND BLEOMYCIN (VICOP-B) IN THE TREATMENT OF ADVANCED CUTANEOUS T-CELL LYMPHOMA
Autore:
FIERRO M; DOVEIL GC; QUAGLINO P; SAVOIA P; VERRONE A; BERNENGO MG;
Indirizzi:
UNIV TURIN,CLIN DERMATOL 1,VIA CHERASCO 23 I-10126 TURIN ITALY
Titolo Testata:
Dermatology
fascicolo: 3, volume: 194, anno: 1997,
pagine: 268 - 272
SICI:
1018-8665(1997)194:3<268:COEICV>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
NON-HODGKINS-LYMPHOMA; MYCOSIS-FUNGOIDES; SEZARY-SYNDROME; RANDOMIZED TRIAL; FOLLOW-UP; MACOP-B; THERAPY; INTERMEDIATE; CHEMOTHERAPY; DIAGNOSIS;
Keywords:
ANTINEOPLASTIC AGENTS; CUTANEOUS T-CELL LYMPHOMA; IDARUBICIN; VICOP-B REGIMEN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
20
Recensione:
Indirizzi per estratti:
Citazione:
M. Fierro et al., "COMBINATION OF ETOPOSIDE, IDARUBICIN, CYCLOPHOSPHAMIDE, VINCRISTINE, PREDNISONE AND BLEOMYCIN (VICOP-B) IN THE TREATMENT OF ADVANCED CUTANEOUS T-CELL LYMPHOMA", Dermatology, 194(3), 1997, pp. 268-272

Abstract

Background: Response of cutaneous T-cell lymphoma (CTCL) to systemic chemotherapy is unsatisfactory: despite an initially high response rate (RR), duration is always short-lived. Objective: To investigate the capability of a third-generation regimen including idarubicin in improving RR and response duration in CTCL patients. Methods: Twenty-five patients with advanced CTCL (stages IIB and IV) were treated with a 12-week polychemotherapeutic regimen (VICOP-B), which foresees the use ofidarubicin in association with etoposide, cyclophosphamide, vincristine, prednisone and bleomycin., Results: The overall objective RR was 80% (36% complete response), The mycosis fungoides (MF) RR was 84%, with a median duration of 8.7 months, The pleomorphic-lymphoma RR was higher (100%), but the corresponding response duration was shorter (median: 3 months), No responses were documented in Sezary syndrome. Conclusion: VICOP-B regimen is effective and feasible as first-line chemotherapy in advanced MF, with or without extracutaneous involvement.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/11/20 alle ore 13:35:16